Lantheus is a radiopharmaceutical-focused company developing diagnostic and therapeutic innovations. The company emphasizes life-changing science and highlights a roughly 70-year operating history.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07364071 |
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer |
RECRUITING | PHASE2 |
| NCT03976843 |
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
